Vamorolone Demonstrates Glucocorticoid Activity Without Clinically Meaningful Immunosuppression in Phase I Study
核心洞察
Catalyst Pharmaceuticals reported positive Phase I results showing vamorolone (Agamree) delivers anti-inflammatory activity without significant immunosuppression at clinical doses.
Part A demonstrated comparable cortisol suppression between vamorolone and deflazacort, supporting switching without dosing adjustments.
Part B found clinically relevant immunosuppression only at supratherapeutic doses (40 mg/kg/day), well above approved dosing levels.
Catalyst Pharmaceuticals announced topline results from a two-part Phase 1 clinical study demonstrating that vamorolone (Agamree) achieves on-target glucocorticoid and anti-inflammatory activity without evidence of clinically meaningful immunosuppression at therapeutic doses. The findings, reported on June 30, 2026, support the drug's potential expansion beyond its currently approved indication in Duchenne muscular dystrophy (搜索) (DMD) into a broader range of chronic inflammatory rare diseases.
The study, conducted in healthy adult volunteers, was designed to assess vamorolone's equipotency with deflazacort (Emflaza) and evaluate its immunosuppressive potential across ascending dose levels.
Part A: Equipotency with Deflazacort
Part A enrolled 24 healthy adults in a randomized, single-center, crossover study comparing single doses of vamorolone (300 mg) with deflazacort (0.9 mg/kg). Both agents demonstrated expected on-target glucocorticoid receptor (搜索) activity, including cortisol suppression, leukocyte redistribution, and effects on functional immune biomarkers. Time to onset was similar for both treatments, occurring approximately two to four hours post-dose.
Importantly, comparable cortisol suppression was observed at clinical doses, while vamorolone produced less pronounced immunosuppressive biomarker effects compared with deflazacort.
"By demonstrating similar cortisol suppression at label-based clinical doses of vamorolone and deflazacort, these data support the currently labeled dosing of vamorolone in the treatment of DMD and do not suggest the need for other dosing considerations when switching patients from deflazacort to vamorolone," said William Andrews, MD, Chief Medical Officer of Catalyst Pharmaceuticals. "Moreover, vamorolone achieved robust glucocorticoid and anti-inflammatory activity without evidence of significant immunosuppression at clinical doses."
Part B: Ascending Dose Evaluation
Part B enrolled 36 healthy volunteers who received vamorolone at daily doses of 9, 27, or 40 mg/kg for seven days, with immune biomarkers and cellular markers evaluated through Day 21. Clinically relevant immunosuppressive effects were observed only at the highest dose level of 40 mg/kg/day. No relevant immunosuppressive effects were detected at the lower dose levels of 9 or 27 mg/kg/day. At the 40 mg/kg/day dose, immunosuppressive effects increased with repeated dosing and persisted after treatment cessation.
"As the 40 mg/kg/day dose is above currently approved vamorolone dosing and higher than doses previously studied in clinical trials, these findings suggest that clinically meaningful immunosuppression with vamorolone is unlikely at clinically relevant doses," Dr. Andrews added. "The prospect of this favorable profile—glucocorticoid and anti-inflammatory activity without clinically meaningful immunosuppression at clinically relevant doses—has the potential to distinguish vamorolone from conventional corticosteroids."
Differentiation from Conventional Corticosteroids
The reduced immunosuppressive activity observed with vamorolone may translate to a lower risk of infection and immune-related adverse effects commonly associated with chronic corticosteroid use. This profile could position vamorolone as a differentiated therapeutic option across multiple chronic inflammatory rare diseases.
Catalyst Pharmaceuticals holds exclusive commercialization rights for Agamree in North America under a 2023 licensing agreement with Santhera (搜索), covering both DMD and any future indications. Santhera retains the right of first negotiation for new indication rights outside North America, along with sales-based milestone payments and royalties across all commercialized indications.
Corporate Context
The positive Phase I data arrive as Catalyst Pharmaceuticals moves toward its planned acquisition by Angelini Pharma (搜索) in a transaction valued at approximately $4.1 billion. Under the definitive agreement announced in May 2026, Angelini Pharma will acquire Catalyst for $31.50 per share in cash. The deal has received unanimous board approval from both companies and is expected to close during the third quarter of 2026, subject to shareholder and regulatory approvals. The acquisition would mark Angelini Pharma's entry into the U.S. market while expanding its rare disease and brain health portfolio.